GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Dabur India Ltd
Dabur India Receives US FDA Warning Letter for Silvassa Plant
REGULATORY ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 06 Aug 2026, 06:41 PM IST  ·  BSE ID: 3fd18fd8-ba07-4fcf-838a-fd580aa6b2de
View Original BSE Filing (PDF)
💡
In Simple Terms
Dabur India received a US government warning about its Silvassa plant for data errors; it is fixing the issues.
🤖 AI Summary
  • US FDA issued a Warning Letter regarding data integrity and maintenance lapses at Dabur India's Silvassa plant.
  • Import Alert IA 66-40 was issued on June 10, 2026, for drugs manufactured at the Silvassa facility.
  • The company has provided four progress updates on corrective actions, with substantial parts completed.
  • The issue concerns a small part of exports for private label products and does not impact domestic sales.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Import Alert number
IA 66-40
Import Alert Date
June 10, 2026
🏢 How This Affects the Company
📈
Business Impact
The Import Alert and Warning Letter may impact future export sales of specific private label products manufactured at the Silvassa facility. Domestic product sales from the plant are not affected.
💰
Financial Impact
While the financial impact is stated to be insignificant as it concerns a small portion of export revenue, ongoing remediation costs and potential delays in export shipments could affect margins.
⚙️
Operational Impact
The company is implementing significant corrective actions, including enhanced training, system upgrades, and engagement of an independent consultant, to address data integrity and maintenance protocols at the Silvassa plant.
⚠️
Risk Impact
This increases regulatory risk associated with US FDA compliance for the Silvassa facility. The company is actively mitigating these risks through comprehensive action plans and engagement.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Shareholders should monitor further updates on the US FDA compliance status.
👤
Who Is Affected
Shareholders invested in Dabur India Ltd. are affected by potential operational and business impacts related to the US FDA actions.
🔍
Management Signal
The management signal is one of proactive engagement and commitment to rectifying regulatory compliance issues at the Silvassa plant.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
US FDA's response to revised corrective action plan updates.
Status of remediation completion and verification by US FDA.
Any impact on future export shipments from the Silvassa plant.
MEDIUM RISK US FDA Warning Letter and Import Alert indicate significant regulatory compliance concerns.
💡 Investor Takeaway
Dabur India received a US FDA Warning Letter and Import Alert for its Silvassa plant due to data integrity issues, impacting a small portion of exports. The company is implementing corrective actions.
⚖️ Strengths & Concerns

✅ Positives

  • Company has provided four detailed progress updates on remediation activities to the US FDA.
  • Substantial parts of mitigating actions, including data integrity training, have already been completed.

⚠️ Concerns

  • US FDA has issued an Import Alert (IA 66-40) on June 10, 2026, for drugs manufactured at the Silvassa plant.
  • The company is in receipt of a Warning Letter summarizing identified data integrity and maintenance lapses.
📅 Company Track Record
Dabur India has previously faced regulatory actions, including an FSSAI order restricting product label claims and a penalty, for which the company planned an appeal.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What actions has the US FDA taken regarding Dabur India's Silvassa plant?
The US FDA issued an Import Alert IA 66-40 on June 10, 2026, and has issued a Warning Letter following an inspection that identified data integrity and maintenance lapses.
Does the US FDA action affect all of Dabur India's products?
No, the issue concerns only a small part of the Silvassa plant's manufacturing for export of private label products; domestic products are not impacted.
What corrective actions is Dabur India taking?
Dabur India is implementing data integrity training, deploying additional resources for oversight, closing infrastructure gaps, and engaging a US-based compliance consulting firm.
When did Dabur India file this update regarding the US FDA action?
Dabur India filed this update on August 06, 2026, in continuation of earlier intimations dated June 1, 2026, and June 11, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.